SAB Biotherapeutics (SABS) Insider Trading & Ownership $2.21 +0.06 (+2.79%) Closing price 04:00 PM EasternExtended Trading$2.19 -0.02 (-0.90%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SAB Biotherapeutics (NASDAQ:SABS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage27.77%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$23.12KNumber OfInsiders Selling(Last 3 Years)0 Get SABS Insider Trade Alerts Want to know when executives and insiders are buying or selling SAB Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SABS Insider Buying and Selling by Quarter SAB Biotherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/7/2023Eddie Joe SullivanCEOBuy1,740$0.88$1,531.20 11/30/2023Michael KingCFOBuy5,000$0.90$4,500.00 11/29/2023Samuel J ReichChairmanBuy11,000$0.89$9,790.00 9/13/2022Christine E HamiltonDirectorBuy10,000$0.73$7,300.00 (Data available from 1/1/2013 forward) SABS Insider Trading Activity - Frequently Asked Questions Who is on SAB Biotherapeutics' Insider Roster? The list of insiders at SAB Biotherapeutics includes Christine E Hamilton, Eddie Joe Sullivan, Michael King, and Samuel J Reich. Learn more on insiders at SABS. What percentage of SAB Biotherapeutics stock is owned by insiders? 27.77% of SAB Biotherapeutics stock is owned by insiders. Learn more on SABS's insider holdings. Which SAB Biotherapeutics insiders have been buying company stock? The following insiders have purchased SABS shares in the last 24 months: Eddie Joe Sullivan ($1,531.20), Michael King ($4,500.00), and Samuel J Reich ($9,790.00). How much insider buying is happening at SAB Biotherapeutics? Insiders have purchased a total of 17,740 SABS shares in the last 24 months for a total of $15,821.20 bought. SAB Biotherapeutics Key ExecutivesMr. Samuel J. Reich (Age 49)CEO & Executive Chairman Compensation: $363.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President & Director Compensation: $402.56kMs. Christine E. Hamilton M.B.A. (Age 68)Co-Founder & Independent Director Compensation: $25kMr. Michael George King Jr. (Age 63)EVP & CFO Compensation: $60.58kDr. Christoph Bausch M.B.A. (Age 53)Ph.D., Executive VP & COO Compensation: $443.2kDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Executive VP & Chief Medical Officer Compensation: $774.45kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverDr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory Affairs More Insider Trading Tools from MarketBeat Related Companies ACHV Insider Trading DOMH Insider Trading FBIO Insider Trading BOLT Insider Trading AMGN Insider Trading GILD Insider Trading VRTX Insider Trading REGN Insider Trading ALNY Insider Trading BIIB Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried? This page (NASDAQ:SABS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access